IMNM logo

IMNM Immunome, Inc.

NASDAQ · Biotechnology · Healthcare

$15.69
-0.92 (-5.54%)

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine …

Market Cap: $1.85Bwww.immunome.com

Price

No data yet.

Social Signal Score

59
5d
—
30d
60
4 mentions
—
60d
58
6 mentions
—
90d
60
7 mentions
—
news: 7

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 13Hold 1Sell 0Strong Sell 0
Avg price target$32.4+106.5%
Low $24Median $35High $37
Current Consensus

Revenue

$0.00
$0.00$1.42M$2.84M$4.26M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-2.24
$-2.32–$-2.13
10 analysts
FY2026
$-2.51
$-2.81–$-2.23
12 analysts
FY2027
$-2.58
$-2.84–$-2.27
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Clay Siegall
Sector
Healthcare
Industry
Biotechnology
Employees
267
Beta
2.13
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
18.29
www.immunome.com